51
|
Hopman H, Chan S, Chu W, Lu H, Lam L, Mak A, Kahn R, Neggers S. Resting-state fMRI biomarkers and effects of transcranial magnetic stimulation in treatment-refractory depression. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
52
|
Chow E, Chan S, Yao Z, Sutradhar R, Lee J, Wan BA, Paszat L. Abstract P3-12-05: Fractionation patterns in adjuvant breast radiotherapy in Ontario, Canada from 2009 to 2015. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To report the patterns of use of hypofractionated radiotherapy (HFRT) (≤16 fractions)in breast cancer and ductal carcinoma in situ (DCIS) patients in Ontario, Canada from 2009 to 2015 and identify factors related to HFRT use.
Methods: A retrospective cohort study of Ontario women diagnosed with breast cancer or DCIS followed by adjuvant breast or chest wall radiation (RT) from 2009 to 2015 was conducted using data from the Institute for Clinical Evaluative Sciences (ICES). Logistic regression models were used to identify factors associated with HFRT use. Physician was included as a random effect. To calculate the potential amount of time that could be saved if all patients were to receive 16 fractions of HFRT, the number of extra RT treatments after the 16th visit was multiplied by the median amount of time spent to treat one patient at our cancer centre (8.76 minutes). This time was found with Sunnybrook Health Sciences Centre data collected from October 2017 to March 2018 (n=523) and represents the amount of time from when a patient enters the RT unit for treatment setup, until the RT beam is turned off.
Results: A total of 42,072 patients were included. Most patients were aged between 50 and 69 years old (56.7%) with stage I or II breast cancer (74.6%) and had breast conserving surgery (BCS) (76.9%). Half previously received chemotherapy and 7.9% were DCIS patients. Use of sequential boost, simultaneous boost, and regional nodal RT was 17.2%, 3.1%, and 31.7% respectively. Institutional variation in HFRT use ranged from 27.5% to 71.6%. HFRT use has increased in all patient populations over the study period. HFRT use was more common in breast cancer and DCIS patients with BCS than in chest wall and nodal RT. Simultaneous boost (OR=0.09), nodal RT (OR=0.08), previous chemotherapy (OR=0.7), stage 0, II, and III breast cancer (OR=0.06 relative to stage I), were correlated with less HFRT use. Older age, later year of diagnosis, sequential boost (OR=0.09), BCS and no surgery (OR=1.2, 1.5 relative to mastectomy) were correlated with higher HFRT use. Institution was significantly correlated to HFRT use. The variance estimate for the physician random effect was 0.33 (p<0.0001). For breast cancer patients with BCS and breast RT specifically, 62,396 extra visits occurred from 2009 to 2015, corresponding to ˜9100 hours of treatment if all patients received HFRT. For the entire patient population, a total of 190,726 extra visits occurred or ˜27,900 hours.
Trends in the use of HFRT (%) from 2009 to 2015 for DCIS and breast cancer patients in Ontario.YearStage I-IV + BCS + Breast RTStage I-IV + BCS + Breast + Nodal RTStage I-IV + Mastectomy + Breast RTStage I-IV + Mastectomy + Breast + Nodal RTDCIS + BCS200962.610.329.09.545.2201062.06.323.76.951.2201162.24.121.34.752.7201263.79.621.711.452.0201365.112.629.315.057.3201469.37.835.415.164.5201573.711.839.217.573.4BCS: breast conserving surgery, RT: radiation treatment
Conclusions: HFRT use in Ontario has increased over time for all patient populations, and reflects the current evidence supporting HFRT in different patient populations, with lower HFRT use seen in chest wall and nodal RT and higher HFRT use in early-stage breast cancer patients with BCS.
Citation Format: Chow E, Chan S, Yao Z, Sutradhar R, Lee J, Wan BA, Paszat L. Fractionation patterns in adjuvant breast radiotherapy in Ontario, Canada from 2009 to 2015 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-05.
Collapse
Affiliation(s)
- E Chow
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - S Chan
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - Z Yao
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - R Sutradhar
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - J Lee
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - BA Wan
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| | - L Paszat
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
| |
Collapse
|
53
|
Alabdullah ML, Ahmad DA, Moseley P, Madhusudan S, Chan S, Rakha E. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer. J OBSTET GYNAECOL 2019; 39:522-528. [PMID: 30712414 DOI: 10.1080/01443615.2018.1534091] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Ovarian cancer is associated with the highest mortality rate among gynaecologic malignancies. There is a need to refine the classification of ovarian cancer and identify novel targets. The mammalian target of rapamycin (mTOR) pathway has a crucial role in the pathogenesis and progression of ovarian cancer. This study aims to investigate the prognostic role of p-mTOR and its major downstream effectors p-4EBP1 (eukaryotic initiation factor 4E-binding protein 1) and p-P70S6K (ribosomal protein S6 kinase) in ovarian cancer. p-mTOR, p-4EBP1 and p-P70S6K protein expression was assessed on 195 consecutive ovarian epithelial cancers and correlated to clinicopathological features and survival. We found that high cytoplasmic expression of p-4EBP1 and p-P70S6K was associated with a serous type carcinoma (p = .005) and an advanced FIGO stage (p = .012), respectively. Univariate outcome analysis showed an inverse association between a high expression of p-4EBP1 expression and overall ovarian cancer survival (OS; p = .005) and progression-free survival (PFS; p = .005). p-P70S6K showed an inverse association with PFS (p = .001). Multivariate analyses indicated that p-4EBP1 was an independent predictor of both OS and PFS (p = .016 and p = .041, respectively). Therefore, we concluded that p-4EBP1 high protein expression is an independent predictor of outcome in ovarian cancer patients. Therefore, it could be used as a potential biomarker for prognostic stratification and treatment decisions. Impact statement What is already known on this subject? The mammalian target of rapamycin (mTOR) pathway has a crucial role in the pathogenesis and progression of ovarian cancer. To-date, very limited knowledge is known about the importance of mTOR major downstream effectors p-4EBP1 (eukaryotic initiation factor 4E-binding protein 1) and p-P70S6K (ribosomal protein S6 kinase) in ovarian cancer. What do the results of this study add? In this study, we have provided further evidence of the adverse prognostic behaviour associated with the positive expression of p-mTOR and its major downstream effectors. Moreover and by performing multivariate analysis, we for the first time have proved that p-4EBP1 is an independent predictor of clinical outcome in ovarian cancer. What are the implications of these findings for clinical practice and/or further research? p-4EBP1 could be used as a potential biomarker for prognostic stratification and treatment decisions in ovarian cancer management.
Collapse
Affiliation(s)
- M L Alabdullah
- a Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine , University of Nottingham , Nottingham , UK.,b Paediatric Surgery Department , Birmingham Children's Hospital NHS Trust , Birmingham , UK
| | - D A Ahmad
- c Department of Histopathology, Division of Cancer and Stem cells, School of Medicine , University of Nottingham , Nottingham , UK
| | - P Moseley
- d Department of Oncology , Nottingham University Hospital , Nottingham , UK
| | - S Madhusudan
- d Department of Oncology , Nottingham University Hospital , Nottingham , UK.,e Translational Oncology, Division of Cancer and Stem Cells, School of Medicine , University of Nottingham , UK
| | - S Chan
- d Department of Oncology , Nottingham University Hospital , Nottingham , UK
| | - E Rakha
- c Department of Histopathology, Division of Cancer and Stem cells, School of Medicine , University of Nottingham , Nottingham , UK
| |
Collapse
|
54
|
Chan S, Brophy M, Nishimura N, Schaffer CB. Aspirin treatment does not increase microhemorrhage size in young or aged mice. PLoS One 2019; 14:e0204295. [PMID: 30608925 PMCID: PMC6319729 DOI: 10.1371/journal.pone.0204295] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Accepted: 12/17/2018] [Indexed: 11/25/2022] Open
Abstract
Microhemorrhages are common in the aging brain and are thought to contribute to cognitive decline and the development of neurodegenerative diseases, such as Alzheimer’s disease. Chronic aspirin therapy is widespread in older individuals and decreases the risk of coronary artery occlusions and stroke. There remains a concern that such aspirin usage may prolong bleeding after a vessel rupture in the brain, leading to larger bleeds that cause more damage to the surrounding tissue. Here, we aimed to understand the influence of aspirin usage on the size of cortical microhemorrhages and explored the impact of age. We used femtosecond laser ablation to rupture arterioles in the cortex of both young (2–5 months old) and aged (18–29 months old) mice dosed on aspirin in their drinking water and measured the extent of penetration of both red blood cells and blood plasma into the surrounding tissue. We found no difference in microhemorrhage size for both young and aged mice dosed on aspirin, as compared to controls (hematoma diameter = 104 +/- 39 (97 +/- 38) μm in controls and 109 +/- 25 (101 +/- 28) μm in aspirin-treated young (aged) mice; mean +/- SD). In contrast, young mice treated with intravenous heparin had an increased hematoma diameter of 136 +/- 44 μm. These data suggest that aspirin does not increase the size of microhemorrhages, supporting the safety of aspirin usage.
Collapse
Affiliation(s)
- Sandy Chan
- Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America
| | - Morgan Brophy
- Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America
| | - Nozomi Nishimura
- Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America
| | - Chris B. Schaffer
- Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York, United States of America
- * E-mail:
| |
Collapse
|
55
|
Wheeler J, Chan S, Harrigan PR, Becker M, Kasper K, Keynan Y. Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada. Int J STD AIDS 2018. [PMID: 29513131 DOI: 10.1177/0956462418760426] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- J Wheeler
- 1 Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
| | - S Chan
- 2 Manitoba HIV Program, Winnipeg, Canada
| | - P R Harrigan
- 3 BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
| | - M Becker
- 1 Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.,2 Manitoba HIV Program, Winnipeg, Canada.,4 Department of Medical Microbiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.,5 Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
| | - K Kasper
- 1 Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.,2 Manitoba HIV Program, Winnipeg, Canada
| | - Y Keynan
- 1 Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.,2 Manitoba HIV Program, Winnipeg, Canada.,4 Department of Medical Microbiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.,5 Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
| |
Collapse
|
56
|
Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. Support Care Cancer 2018; 27:2699-2705. [DOI: 10.1007/s00520-018-4564-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Accepted: 11/20/2018] [Indexed: 12/29/2022]
|
57
|
van Dams R, Shaverdian N, Raghavan G, Chan S, Lee P. The Effect of SBRT Treatment Duration for Early Stage NSCLC on Control Rates, Survival and Toxicity. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
58
|
Raghavan G, Shaverdian N, Chan S, Chu F, Lee P. Comparing Outcomes of Patients with Early Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy Based on Frailty Status. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
59
|
Chan S. ALGORITHM FOR THE DIAGNOSIS AND TREATMENT OF EXERCISE-INDUCED BRONCHOSPASM. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
60
|
Kiss-Lane T, Spruijt O, Day T, Lam V, Ramchandran KJ, Chan S, Hsin G, Vallath N, Bhatnagar S, Rajagopal MR, Lorenz KA. Palliative care clinicians and online education in India: a survey. BMJ Support Palliat Care 2018; 9:e35. [PMID: 30301753 DOI: 10.1136/bmjspcare-2018-001546] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 08/20/2018] [Accepted: 08/29/2018] [Indexed: 11/04/2022]
Abstract
BACKGROUND Whether online resources can facilitate spread of palliative care knowledge and skills in India is an urgent question given few providers and a large, ageing population. OBJECTIVES We surveyed needs and feasibility regarding e-learning. METHODS Indian, Australian and North American palliative care experts developed an electronic survey using Qualtrics, emailed to all registrants of the 2017 Indian Association of Palliative Care (IAPC) conference and distributed during the conference. RESULTS Of 60 respondents (66% men, 60% doctors), most worked in hospitals and had oncology backgrounds, and 35% were from Kerala and Tamil Nadu. Most (90.9%) received palliative care training in India or overseas with 41% trained in a Trivandrum Institute of Palliative Sciences residential course (4-6 weeks). 17% completed the IAPC essential certificate and 22% had undertaken various distance learning courses. Interest in online training was substantial for most aspects of palliative care. CONCLUSION There was a high level of interest and reported feasibility in taking a case-based online course. This pilot survey provides support for online case-based education in India, particularly among physicians.
Collapse
Affiliation(s)
- Tayler Kiss-Lane
- Department of Medicine, Section of Palliative Care, Stanford University School of Medicine, Stanford, California, USA
| | - Odette Spruijt
- Peter MacCallum Cancer Centre, VCCC, Melbourne, Victoria, Australia.,Dentistry and Health, University of Melbourne, Melbourne, Victoria, Australia
| | - Thomas Day
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Vivian Lam
- Department of Medicine, Section of Palliative Care, Stanford University School of Medicine, Stanford, California, USA
| | - Kavitha J Ramchandran
- Department of Medicine, Section of Palliative Care, Stanford University School of Medicine, Stanford, California, USA
| | - Sandy Chan
- Palliative Care, Stanford Health Care, Palo Alto, California, USA
| | - Gary Hsin
- Department of Medicine, Section of Palliative Care, Stanford University School of Medicine, Stanford, California, USA.,Hospice and Palliative Medicine, VA Palo Alto Health Care System, Palo Alto, California, USA
| | - Nandini Vallath
- Divison of Palliative Care, Tata Trusts Cancer Care Program, Mumbai, India
| | - Sushma Bhatnagar
- Onco-Ansesthesia, Pain and Palliative Care, All India Institute of Medical Sciences, New Delhi, India
| | - M R Rajagopal
- Department of Research and Training, Trivandrum Institute of Palliative Sciences, Thiruvananthapuram, Kerala, India
| | - Karl A Lorenz
- Department of Medicine, Section of Palliative Care, Stanford University School of Medicine, Stanford, California, USA.,Hospice and Palliative Medicine, VA Palo Alto Health Care System, Palo Alto, California, USA
| |
Collapse
|
61
|
Krivorotko P, Karaszewska B, Chan S, Wieczorek-Rutkowska M, Sarosiek T, Shomova M, Ovchinnikova E, Zarate J, Babanrao Pisal C, Smith L, Manikhas A. A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
62
|
Chan S, Chan A. What Do Cancer Patients Value? A Unique Experience at Maggie's Cancer Caring Centre in Hong Kong. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.38100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: Maggie's Cancer Caring Centre in Hong Kong (“Maggie's HK”) adopted a person-centered approach advocated by Maggie Keswick Jencks, who was the founder and a cancer patient. Witnessing first-hand that many psychosocial needs of a cancer patient could not be met through the existing medical system, Maggie created a blueprint for a purposefully-designed architecture and the services complementary to the existing system. The centre aims to empower people affected by cancer, be they cancer patients or caregivers, to live with, live through and live beyond cancer via informational and psychological consultations, psychosocial support programs and a therapeutic environment. People in need are welcome to drop-in anytime to use the centre while all services/programs are free and no referral/appointment is needed. As this patient-oriented drop-in service, integrated multidisciplinary approach and the therapeutic architecture, as one of a kind would conceptually make people feel at home, feel respected, see themselves as a person rather than a patient, and gain confidence in facing and walking through the cancer journey, how does this translate into practice in Maggie's HK? Aim: To examine the uniqueness of Maggie's HK cancer care service, especially the patient-oriented drop-in service and the purposefully-designed environment, this study investigated cancer patients' related experience at Maggie's HK and its influences on their cancer adjustment and adaptive coping in the community. Methods: A qualitative study design was adopted. Thirteen semistructured focus group interviews, each with 5-6 cancer patients/care-givers at Maggie's HK, were held from August 2016 to January 2017. Each interview lasted from 1.5 to 2.5 hours and were audio recorded then transcribed verbatim. Different themes were generated through repeated readings and content analysis with constant comparison. Results: Three main themes regarding the unique experiences of the drop-in service model under a purposefully-designed environment at Maggie's HK were emerged from the focus groups: Creating a sense of home for the centre users. Users reported the centre is like their second home giving them a sense of autonomy, security, trust and comfort. Empowering users to deal with uncertainties. Users reported the (drop-in) service helps to reduce their fear, worries and doubts. Providing a nurturing context for users' needs. Users reported the design of the physical environment has catered to their specific needs at different moments in time. Conclusion: The study reveals that the innovative model of patient-oriented drop-in service under a therapeutic physical environment at Maggie's HK contributes significantly a positive experience and impact on cancer patients in the reduction of their fear and worries, while enhancing their role as active participants in their care. There is also a developed sense of autonomy, security and confidence in the cancer journey.
Collapse
Affiliation(s)
- S. Chan
- Maggie's Cancer Caring Centre, Tuen Mun, Hong Kong, China
| | - A. Chan
- Maggie's Cancer Caring Centre, Tuen Mun, Hong Kong, China
| |
Collapse
|
63
|
Leung L, Hung K, Lo R, Yeung C, Chan S, Graham C. 6 Prognostic Value of qSOFA, SIRS and News in the Emergency Department for Predicting 7-Day Mortality: A Prospective Study. Ann Emerg Med 2018. [DOI: 10.1016/j.annemergmed.2018.08.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
64
|
Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh C, Hasan J, Ograbek A, Perren T. Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
65
|
Amaudruz PA, Baldwin M, Batygov M, Beltran B, Bina CE, Bishop D, Bonatt J, Boorman G, Boulay MG, Broerman B, Bromwich T, Bueno JF, Burghardt PM, Butcher A, Cai B, Chan S, Chen M, Chouinard R, Cleveland BT, Cranshaw D, Dering K, DiGioseffo J, Dittmeier S, Duncan FA, Dunford M, Erlandson A, Fatemighomi N, Florian S, Flower A, Ford RJ, Gagnon R, Giampa P, Golovko VV, Gorel P, Gornea R, Grace E, Graham K, Gulyev E, Hakobyan R, Hall A, Hallin AL, Hamstra M, Harvey PJ, Hearns C, Jillings CJ, Kamaev O, Kemp A, Kuźniak M, Langrock S, La Zia F, Lehnert B, Lidgard JJ, Lim C, Lindner T, Linn Y, Liu S, Majewski P, Mathew R, McDonald AB, McElroy T, McGinn T, McLaughlin JB, Mead S, Mehdiyev R, Mielnichuk C, Monroe J, Muir A, Nadeau P, Nantais C, Ng C, Noble AJ, O'Dwyer E, Ohlmann C, Olchanski K, Olsen KS, Ouellet C, Pasuthip P, Peeters SJM, Pollmann TR, Rand ET, Rau W, Rethmeier C, Retière F, Seeburn N, Shaw B, Singhrao K, Skensved P, Smith B, Smith NJT, Sonley T, Soukup J, Stainforth R, Stone C, Strickland V, Sur B, Tang J, Taylor J, Veloce L, Vázquez-Jáuregui E, Walding J, Ward M, Westerdale S, Woolsey E, Zielinski J. First Results from the DEAP-3600 Dark Matter Search with Argon at SNOLAB. Phys Rev Lett 2018; 121:071801. [PMID: 30169081 DOI: 10.1103/physrevlett.121.071801] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 05/17/2018] [Indexed: 06/08/2023]
Abstract
This Letter reports the first results of a direct dark matter search with the DEAP-3600 single-phase liquid argon (LAr) detector. The experiment was performed 2 km underground at SNOLAB (Sudbury, Canada) utilizing a large target mass, with the LAr target contained in a spherical acrylic vessel of 3600 kg capacity. The LAr is viewed by an array of PMTs, which would register scintillation light produced by rare nuclear recoil signals induced by dark matter particle scattering. An analysis of 4.44 live days (fiducial exposure of 9.87 ton day) of data taken during the initial filling phase demonstrates the best electronic recoil rejection using pulse-shape discrimination in argon, with leakage <1.2×10^{-7} (90% C.L.) between 15 and 31 keV_{ee}. No candidate signal events are observed, which results in the leading limit on weakly interacting massive particle (WIMP)-nucleon spin-independent cross section on argon, <1.2×10^{-44} cm^{2} for a 100 GeV/c^{2} WIMP mass (90% C.L.).
Collapse
Affiliation(s)
- P-A Amaudruz
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M Baldwin
- Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0QX, United Kingdom
| | - M Batygov
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - B Beltran
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - C E Bina
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - D Bishop
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - J Bonatt
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - G Boorman
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - M G Boulay
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - B Broerman
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - T Bromwich
- University of Sussex, Sussex House, Brighton, East Sussex BN1 9RH, United Kingdom
| | - J F Bueno
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - P M Burghardt
- Department of Physics, Technische Universität München, 80333 Munich, Germany
| | - A Butcher
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - B Cai
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Chan
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M Chen
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Chouinard
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - B T Cleveland
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - D Cranshaw
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - K Dering
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - J DiGioseffo
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Dittmeier
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - F A Duncan
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - M Dunford
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - A Erlandson
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - N Fatemighomi
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - S Florian
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - A Flower
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - R J Ford
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - R Gagnon
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - P Giampa
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - V V Golovko
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - P Gorel
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - R Gornea
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - E Grace
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - K Graham
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - E Gulyev
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - R Hakobyan
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - A Hall
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - A L Hallin
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - M Hamstra
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - P J Harvey
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Hearns
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C J Jillings
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - O Kamaev
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - A Kemp
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - M Kuźniak
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - S Langrock
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - F La Zia
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - B Lehnert
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - J J Lidgard
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Lim
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - T Lindner
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - Y Linn
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S Liu
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - P Majewski
- Rutherford Appleton Laboratory, Harwell Oxford, Didcot OX11 0QX, United Kingdom
| | - R Mathew
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - A B McDonald
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - T McElroy
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - T McGinn
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - J B McLaughlin
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Mead
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - R Mehdiyev
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - C Mielnichuk
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - J Monroe
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - A Muir
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - P Nadeau
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - C Nantais
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Ng
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - A J Noble
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - E O'Dwyer
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Ohlmann
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - K Olchanski
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - K S Olsen
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - C Ouellet
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - P Pasuthip
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S J M Peeters
- University of Sussex, Sussex House, Brighton, East Sussex BN1 9RH, United Kingdom
| | - T R Pollmann
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- Department of Physics, Technische Universität München, 80333 Munich, Germany
| | - E T Rand
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - W Rau
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - C Rethmeier
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - F Retière
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - N Seeburn
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - B Shaw
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - K Singhrao
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - P Skensved
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - B Smith
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - N J T Smith
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - T Sonley
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
| | - J Soukup
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - R Stainforth
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - C Stone
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - V Strickland
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - B Sur
- Canadian Nuclear Laboratories Ltd, Chalk River, Ontario K0J 1J0, Canada
| | - J Tang
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - J Taylor
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - L Veloce
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - E Vázquez-Jáuregui
- Department of Physics and Astronomy, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
- SNOLAB, Lively, Ontario P3Y 1M3, Canada
- Instituto de Física, Universidad Nacional Autónoma de México, A. P. 20-364, México D. F. 01000, Mexico
| | - J Walding
- Royal Holloway University London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - M Ward
- Department of Physics, Engineering Physics, and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Westerdale
- Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - E Woolsey
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - J Zielinski
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| |
Collapse
|
66
|
Chan S, Pullerits K, Riechelmann J, Persson KM, Rådström P, Paul CJ. Monitoring biofilm function in new and matured full-scale slow sand filters using flow cytometric histogram image comparison (CHIC). Water Res 2018; 138:27-36. [PMID: 29571086 DOI: 10.1016/j.watres.2018.03.032] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Revised: 03/09/2018] [Accepted: 03/12/2018] [Indexed: 06/08/2023]
Abstract
While slow sand filters (SSFs) have produced drinking water for more than a hundred years, understanding of their associated microbial communities is limited. In this study, bacteria in influent and effluent water from full-scale SSFs were explored using flow cytometry (FCM) with cytometric histogram image comparison (CHIC) analysis; and routine microbial counts for heterotrophs, total coliforms and Escherichia coli. To assess if FCM can monitor biofilm function, SSFs differing in age and sand composition were compared. FCM profiles from two established filters were indistinguishable. To examine biofilm in the deep sand bed, SSFs were monitored during a scraping event, when the top layer of sand and the schmutzdecke are removed to restore flow through the filter. The performance of an established SSF was stable: total organic carbon (TOC), pH, numbers of heterotrophs, coliforms, E. coli, and FCM bacterial profile were unaffected by scraping. However, the performance of two newly-built SSFs containing new and mixed sand was compromised: breakthrough of both microbial indicators and TOC occurred following scraping. The compromised performance of the new SSFs was reflected in distinct effluent bacterial communities; and, the presence of microbial indicators correlated to influent bacterial communities. This demonstrated that FCM can monitor SSF performance. Removal of the top layer of sand did not alter the effluent water from the established SSF, but did affect that of the SSFs containing new sand. This suggests that the impact of the surface biofilm on effluent water is greater when the deep sand bed biofilm is not established.
Collapse
Affiliation(s)
- Sandy Chan
- Applied Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden; Sweden Water Research AB, Ideon Science Park, Scheelevägen 15, SE-223 70 Lund, Sweden; Sydvatten AB, Hyllie Stationstorg 21, SE-215 32 Malmö, Sweden.
| | - Kristjan Pullerits
- Applied Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden; Sweden Water Research AB, Ideon Science Park, Scheelevägen 15, SE-223 70 Lund, Sweden; Sydvatten AB, Hyllie Stationstorg 21, SE-215 32 Malmö, Sweden.
| | - Janine Riechelmann
- Applied Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden.
| | - Kenneth M Persson
- Sweden Water Research AB, Ideon Science Park, Scheelevägen 15, SE-223 70 Lund, Sweden; Sydvatten AB, Hyllie Stationstorg 21, SE-215 32 Malmö, Sweden; Water Resources Engineering, Department of Building and Environmental Technology, Lund University, P.O. Box 118, SE-221 00 Lund, Sweden.
| | - Peter Rådström
- Applied Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden.
| | - Catherine J Paul
- Applied Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden; Water Resources Engineering, Department of Building and Environmental Technology, Lund University, P.O. Box 118, SE-221 00 Lund, Sweden.
| |
Collapse
|
67
|
Assaf N, Nagrecha R, Campbell-Smith T, Chan S. Colorectal cancer diagnosis: How satisfied is your patient? Int J Surg 2018. [DOI: 10.1016/j.ijsu.2018.05.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
68
|
Alotaibi K, Higgins I, Day J, Chan S. Paediatric pain management: knowledge, attitudes, barriers and facilitators among nurses - integrative review. Int Nurs Rev 2018; 65:524-533. [PMID: 29956310 DOI: 10.1111/inr.12465] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
AIMS To identify and synthesize evidence regarding the knowledge and attitudes of nurses, and barriers and facilitators to effective pain assessment and management in infants and children. BACKGROUND Pain among children is a common experience. Relief from pain is a fundamental human right, yet hospitalized children continue to experience unrelieved pain. Provision of effective pain management is an integral part of the nurse's role. METHODS Guided by Whittemore & Knafl's five-stage framework, primary peer-reviewed studies published in English between 2000 and 2018 were searched using CINAHL, PubMed, ProQuest, PsycINFO and Scopus. The initial search yielded 292 papers. Twenty-seven papers were included in this review: quantitative (n = 18), qualitative (n = 5) and mixed-methods (n = 4). RESULTS Findings showed that nurses internationally have poor knowledge and attitudes of basic pain assessment and management principles. Barriers to effective pain management include the absence of pain education and assessment tools, parents' reluctance to report pain and insufficient prescription of analgesia by physicians. Facilitators for the effective management of pain include parental participation in care, trusting and respectful relationships between nurses and children, and adequate nurse-patient ratios. CONCLUSION The review findings suggest a need to improve education for nurses, doctors and the patients' family in relation to paediatric pain management, communication and interprofessional collaborations. There is a need to maximize facilitators and overcome barriers, such as those identified in this review, to ensure the quality of paediatric pain management. IMPLICATIONS FOR NURSING AND HEALTH POLICY Nursing and health policy should mandate the prioritization of paediatric pain management and the clinical roles and responsibilities of the interdisciplinary team members. Undergraduate, postgraduate and in-service education for nurses and other health professionals should also address paediatric pain management. In-service education on paediatric pain management should be compulsory for all health professionals caring for children.
Collapse
Affiliation(s)
- K Alotaibi
- School of Nursing and Midwifery, the University of Newcastle, Callaghan NSW 2308, Australia
| | - I Higgins
- School of Nursing and Midwifery, the University of Newcastle, Callaghan NSW 2308, Australia
| | - J Day
- School of Nursing and Midwifery, the University of Newcastle, Callaghan NSW 2308, Australia
| | - S Chan
- Priority Research Centre of Brain and Mental Health, Faculty of Health and Medicine, The University of Newcastle, Callaghan Australia
| |
Collapse
|
69
|
Alabdullah M, Ali R, Moseley P, Chan S, Rakha E, Madhusudan S. PO-236 Human ligase profiling to predict platinum sensitivity and clinical outcome in primary epithelial ovarian cancers. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
70
|
Alabdullah M, Moseley P, Madhusudan S, Chan S, Rakha E. PO-110 AKT expression is associated with poor clinical outcome in ovarian cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
71
|
Tao MJ, Probyn L, Drost L, Kreder H, Nousiainen M, Tsao M, Barnes E, Jenkinson R, Wan BA, Poon M, Chan S, Chow E. Efficacy of Prophylactic Radiotherapy in the Treatment of Heterotopic Ossification. Clin Oncol (R Coll Radiol) 2018; 30:393-395. [DOI: 10.1016/j.clon.2018.02.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 02/12/2018] [Indexed: 11/25/2022]
|
72
|
Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Gounaris I, Abraham JE, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Rea D, Caldas C, Bartlett JMS, Cameron DA, Provenzano E, Thomas J, Hayward RL. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. Ann Oncol 2018; 28:1817-1824. [PMID: 28459938 PMCID: PMC5834079 DOI: 10.1093/annonc/mdx173] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Background The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review. Patients and methods Patients were randomized to 3 cycles of D followed by 3 cycles of FEC (D-FEC), ±4 cycles of Bev (Bev + D-FEC). DFS and OS were analyzed by treatment and by central pathology reviewed pCR and Residual Cancer Burden (RCB) class. Results A total of 800 patients were randomized [median follow-up 3.5 years (IQR 3.2–4.4)]. DFS and OS were similar across treatment arms [DFS hazard ratio (HR)=1.18 (95% CI 0.89–1.57), P = 0.25; OS HR = 1.26 (95% CI 0.90–1.76), P = 0.19). Both local pathology report review and central histopathology review confirmed a significant improvement in DFS and OS for patients who achieved a pCR [DFS HR = 0.38 (95% CI 0.23–0.63), P < 0.001; OS HR = 0.43 (95% CI 0.24–0.75), P = 0.003]. However, significant heterogeneity was observed (P = 0.02); larger improvements in DFS were obtained with a pCR achieved with D-FEC than a pCR achieved with Bev + D-FEC. As RCB class increased, significantly worse DFS and OS was observed (P for trend <0.0001), which effect was most marked in the ER negative group. Conclusions The addition of short course neoadjuvant Bev to standard chemotherapy did not demonstrate a DFS or OS benefit. Achieving a pCR with D-FEC is associated with improved DFS and OS but not when pCR is achieved with Bev + D-FEC. At the present time therefore, Bev is not recommended in early breast cancer. ClinicalTrials.gov number NCT01093235.
Collapse
Affiliation(s)
- H M Earl
- Department of Oncology, University of Cambridge, Cambridge.,NIHR Cambridge Biomedical Research Centre, Cambridge.,Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - L Hiller
- Warwick Clinical Trials Unit, University of Warwick, Coventry
| | - J A Dunn
- Warwick Clinical Trials Unit, University of Warwick, Coventry
| | - C Blenkinsop
- Warwick Clinical Trials Unit, University of Warwick, Coventry
| | - L Grybowicz
- Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - A-L Vallier
- Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - I Gounaris
- Department of Oncology, Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn.,Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge
| | - J E Abraham
- Department of Oncology, University of Cambridge, Cambridge.,NIHR Cambridge Biomedical Research Centre, Cambridge.,Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - L Hughes-Davies
- Department of Oncology, University of Cambridge, Cambridge.,Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - K McAdam
- Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge.,Department of Oncology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough
| | - S Chan
- Department of Oncology, Nottingham City Hospital, Nottingham
| | - R Ahmad
- Department of Oncology, West Middlesex University Hospital, Isleworth
| | - T Hickish
- Department of Oncology, Poole Hospital NHS Foundation Trust/Bournemouth University, Poole
| | - D Rea
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, UK
| | - C Caldas
- Department of Oncology, University of Cambridge, Cambridge.,NIHR Cambridge Biomedical Research Centre, Cambridge.,Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge.,Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge
| | - J M S Bartlett
- Ontario Institute for Cancer Research, MaRS Centre, Toronto, Canada.,Cancer Research Centre, University of Edinburgh, IGMM, Western General Hospital, Edinburgh
| | - D A Cameron
- Cancer Research Centre, University of Edinburgh, IGMM, Western General Hospital, Edinburgh
| | - E Provenzano
- NIHR Cambridge Biomedical Research Centre, Cambridge.,Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - J Thomas
- Department of Pathology, University of Edinburgh, Edinburgh, UK
| | - R L Hayward
- Cancer Research Centre, University of Edinburgh, IGMM, Western General Hospital, Edinburgh
| | | |
Collapse
|
73
|
Kowitlawkul Y, Yap S, Makabe S, Chan S, Takagai J, Tam W, Nurumal M. Investigating nurses’ quality of life and work-life balance statuses in Singapore. Int Nurs Rev 2018; 66:61-69. [DOI: 10.1111/inr.12457] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Y. Kowitlawkul
- Alice Lee Centre for Nursing Studies/Yong Loo Lin School of Medicine; National University of Singapore; Singapore Singapore
| | - S.F. Yap
- Advanced Practice Nurse; Khoo Teck Puat Hospital; Singapore Singapore
| | - S. Makabe
- Department of Clinical Nursing; Akita University; Akita Japan
| | - S. Chan
- School of Nursing and Midwifery; University of Newcastle; Newcastle NSW Australia
| | - J. Takagai
- Department of Clinical Nursing; Akita University; Akita Japan
| | - W.W.S. Tam
- Alice Lee Centre for Nursing Studies/Yong Loo Lin School of Medicine; National University of Singapore; Singapore Singapore
| | - M.S. Nurumal
- Kulliyyah of Nursing; International Islamic University Malaysia; Kuantan Malaysia
| |
Collapse
|
74
|
Lai A, Toh L, Zhuang K, Tan B, Tay K, Irani F, Damodharan K, Chan S, Too C, Lo R, Patel A, Gogna A, Chandramohan S. 3:27 PM Abstract No. 64 Radiological retrograde ureteric stent exchange: a large single-center review. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
75
|
Chan S, Pudwell J, Smith G. Effects of Pre-Eclampsia on Maternal and Paediatric Health at 10 Years Postpartum. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.01.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
76
|
Alabdullah M, Moseley P, Chan S, Rakha E, Madhusudan S. Clinicopathological, predictive and prognostic significance of XRCC1-Ligase III heterodimer expression in ovarian cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
77
|
Alabdullah M, Miligy I, Moseley P, Madhusudan S, Chan S, Rakha E. mTORC1 and its downstream effectors predict poor outcome in primary epithelial ovarian cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
78
|
Chan S, Cardamone MD, Perissi V. Abstract P2-08-02: Novel tumor suppressor regulating the PI3K/AKT pathway in breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-08-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer affects approximately 1 in 8 women over the course of their lifetime. Of the many genes and pathways deregulated by this heterogeneous disease, alterations of members in the PI3K/AKT pathway are present in approximately 20% of all cases, making it one of the more frequently mutated pathways in breast cancer. The PI3K/AKT pathway is well known to be involved in essential cellular processes necessary for cancer development and progression, including altered proliferation, metabolism, and cell survival. Previous studies have made it well known that the activation of AKT is regulated through its phosphorylation, but recent studies have also shown that AKT can also be regulated via ubiquitination, leading to AKT hyperactivation. However, the mechanism and players involved in this process are not well understood. Better understanding of these pathways could inform on better potential therapeutics to target this disease.
Recent work in our lab has identified GPS2, a member of the NCoR/SMRT complex, as a regulator of the insulin-signaling pathway through the inhibition of AKT ubiquitination by Ubc13. As many human cancers frequently have an increase in activated AKT, here we explore the potential of GPS2 as a tumor suppressor in the context of breast cancer and hope to elucidate the mechanism by which AKT ubiquitination regulates its activation.
Citation Format: Chan S, Cardamone MD, Perissi V. Novel tumor suppressor regulating the PI3K/AKT pathway in breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-08-02.
Collapse
Affiliation(s)
- S Chan
- Boston University School of Medicine, Boston, MA
| | - MD Cardamone
- Boston University School of Medicine, Boston, MA
| | - V Perissi
- Boston University School of Medicine, Boston, MA
| |
Collapse
|
79
|
Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Res Treat 2017; 168:357-364. [PMID: 29198055 DOI: 10.1007/s10549-017-4596-7] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2017] [Accepted: 11/22/2017] [Indexed: 11/27/2022]
Abstract
PURPOSE A Phase Ib study in patients with trastuzumab-resistant, human epidermal growth factor receptor-2- (HER2)-positive advanced breast cancer defined the recommended Phase II dose of buparlisib as 100 mg/day in combination with 2 mg/kg weekly trastuzumab, and reported preliminary signs of clinical activity. Here we present results from the Phase II portion. METHODS Patients with trastuzumab-resistant, HER2-positive advanced breast cancer received buparlisib plus trastuzumab. Study endpoints included safety/tolerability and antitumour activity. The study was extended to include a Phase Ib dose-escalation phase, in which patients with progressive brain metastases also received capecitabine. RESULTS In the Phase II portion, of 50 patients treated with buparlisib and trastuzumab, the most common (≥ 30%) all-grade adverse events (AEs) were diarrhoea (54%), nausea (48%), decreased appetite, increased alanine aminotransferase (36% each), increased aspartate aminotransferase (34%), fatigue, rash (32% each), cough and hyperglycemia (30% each). One (2%) patient achieved complete response and four (8%) patients had confirmed partial responses [PR; including two patients with phosphatidylinositol 3-kinase (PI3 K) pathway-activated tumours]. Overall response rate (ORR) was 10%: the primary endpoint (ORR ≥ 25%) was therefore not met. In the Phase Ib portion, all patients with measurable brain lesions at baseline showed tumour shrinkage to some degree; due to low enrollment, maximum tolerated dose of buparlisib in combination with trastuzumab and capecitabine was not determined. CONCLUSION Buparlisib plus trastuzumab, as a chemotherapy-free regimen, demonstrated an acceptable safety profile but limited efficacy in patients with heavily pretreated, trastuzumab-resistant HER2-positive breast cancer, and in patients with progressive brain metastases also receiving capecitabine.
Collapse
Affiliation(s)
- B Pistilli
- Breast Cancer Unit, Institut Gustave Roussy, 114 Rue Edouard-Vaillant, 94800, Villejuif, France. .,Macerata Hospital, Macerata, Italy.
| | - T Pluard
- Saint Luke's Health System, Kansas City, MO, USA
| | - A Urruticoechea
- Onkologikoa Foundation, San Sebastian, Spain.,Catalan Institute of Oncology, Barcelona, Spain
| | - D Farci
- Ospedale Oncologico, Cagliari, Italy
| | - A Kong
- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.,University of Oxford and Oxford University Hospitals NHS Trust, Oxford, UK
| | - T Bachelot
- Centre Léon Bérard et Inserm U1052, Lyon, France
| | - S Chan
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - H S Han
- Moffitt Cancer Center, Tampa, FL, USA
| | - G Jerusalem
- CHU Sart Tilman Liège and University of Liège, Liège, Belgium
| | - P Urban
- Novartis Pharma AG, Basel, Switzerland
| | - D Robinson
- Novartis Institutes for BioMedical Research, Cambridge, MA, USA
| | - S L Mouhaër
- Novartis Pharmaceuticals Corporation, Rueil-Malmaison, France
| | - E D Tomaso
- Novartis Institutes for BioMedical Research, Cambridge, MA, USA.,Syros Pharmaceuticals, Watertown, MA, USA
| | - C Massacesi
- Novartis Pharmaceuticals Corporation, Rueil-Malmaison, France
| | - C Saura
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| |
Collapse
|
80
|
Tan T, Ong W, Chan S, Chan J, Chay W, Lim E, Lim S, Soh L, Tan D, Chia J. Interim Analysis of A Single-Arm Phase 2 Clinical Trial of Regorafenib in Patients with Epithelial Ovarian Cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx663.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
81
|
Chan S, Mohamed I, Karandikar S. Appendicitis Over the Age of 40 Years: Should We Image the Colon? Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
82
|
Chan S. P077 Incongruity in detecting dog sensitized individuals between skin prick and specific dog IgE testing. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
83
|
Mejsak A, Decker E, Askari A, Chan S. Socioeconomical Cost of Acute Pilonidal Sinus Surgery in District General Hospital in UK. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
84
|
Raman S, Ganesh V, Chan S, Chow R, Hoskin P, Lam H, Wan B, Drost L, DeAngelis C, Chow E. A Review of Practice Patterns and Clinical Guidelines in the Palliative Radiation Treatment of Uncomplicated Bone Metastases. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
85
|
Khan N, Zhao Y, Rabkin S, Izadnegahdar M, Park J, Guan M, Lee M, Grubisic M, Peng D, Daniele P, Chan S, Humphries K. HOW LOW IS TOO LOW? ANALYSIS OF SYSTOLIC AND DIASTOLIC BLOOD PRESSURE IN PATIENTS WITH AND WITHOUT PRIOR CARDIOVASCULAR DISEASE IN THE SPRINT TRIAL. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.391] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
86
|
Chan S, De Luca J, Douglass J. P13: A MULTIDISCIPLINARY APPROACH TO ANAPHYLAXIS: THE IMPORTANCE OF ED/IMMUNOLOGY LIASON. Intern Med J 2017. [DOI: 10.1111/imj.13_13578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- S Chan
- Royal Melbourne Hospital; Melbourne Australia
| | - J De Luca
- Royal Melbourne Hospital; Melbourne Australia
| | - J Douglass
- Royal Melbourne Hospital; Melbourne Australia
| |
Collapse
|
87
|
De Luca J, Chan S, Collins C, Patel M, Nicholls K, Douglass J. P14: TRENDS IN GENERAL ANAESTHETIC ALLERGY TESTING: THE ROYAL MELBOURNE HOSPITAL EXPERIENCE. Intern Med J 2017. [DOI: 10.1111/imj.14_13578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- J De Luca
- Royal Melbourne Hospital; Melbourne Australia
| | - S Chan
- Royal Melbourne Hospital; Melbourne Australia
| | - C Collins
- Royal Melbourne Hospital; Melbourne Australia
| | - M Patel
- Royal Melbourne Hospital; Melbourne Australia
| | - K Nicholls
- Royal Melbourne Hospital; Melbourne Australia
| | - J Douglass
- Royal Melbourne Hospital; Melbourne Australia
- University of Melbourne; Melbourne Australia
| |
Collapse
|
88
|
Sinha N, Letourneau J, Chan S, Niemasik E, Xiong P, Harris E, Mok-Lin E, Cedars M, Rosen M. Improvement in quality of life with fertility preservation begins after cancer treatment and persists one year after cancer treatment. Fertil Steril 2017. [DOI: 10.1016/j.fertnstert.2017.07.280] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
89
|
Affiliation(s)
- J.K. Davitt
- School of Social Work, University of Maryland, Baltimore, Maryland,
| | - J. Bourjolly
- University of Pennsylvania, Philadelphia, Pennsylvania,
| | - R. Frasso
- University of Pennsylvania, Philadelphia, Pennsylvania,
| | - S. Chan
- Independent Statistics Consultant, Philadelphia, Pennsylvania
| |
Collapse
|
90
|
Kumar A, Lau C, Chan S, Ma M, Kearns W. A LONGITUDINAL STUDY OF THE NAVIGATION PATTERNS OF DEMENTIA PATIENTS AND THEIR RELATIONSHIP TO MMSE. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A. Kumar
- Joint NTU-UBC Research Centre of Excellence in Active Living for the Elderly, Singapore, Singapore,
- IGS, Nanyang Technological University, Singapore, Singapore,
| | - C. Lau
- SCSE, Nanyang Technological University, Singapore, Singapore,
| | - S. Chan
- College of Professional and Continuing Education, Singapore, Singapore,
| | - M. Ma
- EEE, Nanyang Technological University, Singapore, Singapore,
| | - W. Kearns
- University of South Florida, Tampa, Florida
| |
Collapse
|
91
|
Kenbubpha K, Higgins I, Chan S, Wilson A. PROMOTING ACTIVE AGEING IN OLDER PEOPLE WITH MENTAL DISORDERS: DEVELOPMENT AND TESTING OF A TOOL. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K. Kenbubpha
- The University of Newcastle, Newcastle, New South Wales, Australia
| | - I. Higgins
- The University of Newcastle, Newcastle, New South Wales, Australia
| | - S. Chan
- The University of Newcastle, Newcastle, New South Wales, Australia
| | - A. Wilson
- The University of Newcastle, Newcastle, New South Wales, Australia
| |
Collapse
|
92
|
Sun H, Yang M, Fung M, Chan S, Jawi M, Anderson T, Poon MC, Jackson S. Adult males with haemophilia have a different macrovascular and microvascular endothelial function profile compared with healthy controls. Haemophilia 2017. [DOI: 10.1111/hae.13278] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- H. Sun
- Division of Hematology; Department of Medicine; University of British Columbia; Vancouver Canada
- British Columbia Provincial Bleeding Disorders Program-Adult Division; Vancouver Canada
| | - M. Yang
- British Columbia Provincial Bleeding Disorders Program-Adult Division; Vancouver Canada
| | - M. Fung
- Department of Medicine; University of Calgary; Calgary Canada
| | - S. Chan
- Division of Cardiology; Department of Medicine; University of British Columbia; Vancouver Canada
| | - M. Jawi
- Healthy Heart Program; St. Paul's Hospital; University of British Columbia; Vancouver Canada
| | - T. Anderson
- Department of Cardiac Sciences and the Libin Cardiovascular Institute of Alberta; University of Calgary; Calgary Canada
| | - M.-C. Poon
- Division of Hematology; Department of Medicine; University of Calgary; Calgary Canada
- Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program; University of Calgary Foothills Hospital; Calgary Canada
| | - S. Jackson
- Division of Hematology; Department of Medicine; University of British Columbia; Vancouver Canada
- British Columbia Provincial Bleeding Disorders Program-Adult Division; Vancouver Canada
| |
Collapse
|
93
|
Chan S, Chan HP, Corney C, Scuderi C, Selvalogan N, Pelecanos A, Ratanjee S. Phosphate binder use in patients undergoing centre-based haemodialysis within the Metro North Kidney Health Service. Intern Med J 2017. [DOI: 10.1111/imj.4_13461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- S Chan
- Kidney Health Service; Metro North Hospital and Health Service; Brisbane Queensland Australia
- Faculty of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - HP Chan
- Faculty of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - C Corney
- Faculty of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - C Scuderi
- Department of Pharmacy; Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service; Brisbane Queensland Australia
| | - N Selvalogan
- Faculty of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - A Pelecanos
- Metro North Hospital and Health Service Statistical Unit; QIMR Berghofer Medical Research Institute; Brisbane Queensland Australia
| | - S Ratanjee
- Kidney Health Service; Metro North Hospital and Health Service; Brisbane Queensland Australia
- Faculty of Medicine; The University of Queensland; Brisbane Queensland Australia
| |
Collapse
|
94
|
Chan S, Campbell SB, Clayton PA, Mudge DW, Hawley CM, Johnson DW, Francis FS. Temporal changes in deceased kidney donor characteristics in Australia. Intern Med J 2017. [DOI: 10.1111/imj.2_13457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- S Chan
- Australian and New Zealand Dialysis and Transplant Registry; Adelaide Australia
- Department of Nephrology; Princess Alexandra Hospital; Brisbane Queensland Australia
- School of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - SB Campbell
- Department of Nephrology; Princess Alexandra Hospital; Brisbane Queensland Australia
- School of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - PA Clayton
- Australian and New Zealand Dialysis and Transplant Registry; Adelaide Australia
- Central Northern Adelaide Renal and Transplantation Service; Royal Adelaide Hospital; Adelaide Australia
- School of Medicine; University of Adelaide; Adelaide South Australia Australia
| | - DW Mudge
- Department of Nephrology; Princess Alexandra Hospital; Brisbane Queensland Australia
- School of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - CM Hawley
- Australian and New Zealand Dialysis and Transplant Registry; Adelaide Australia
- Department of Nephrology; Princess Alexandra Hospital; Brisbane Queensland Australia
- School of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - DW Johnson
- Australian and New Zealand Dialysis and Transplant Registry; Adelaide Australia
- Department of Nephrology; Princess Alexandra Hospital; Brisbane Queensland Australia
- School of Medicine; The University of Queensland; Brisbane Queensland Australia
| | - FS Francis
- Department of Nephrology; Princess Alexandra Hospital; Brisbane Queensland Australia
- School of Medicine; The University of Queensland; Brisbane Queensland Australia
| |
Collapse
|
95
|
Martinez-Høyer S, Mo A, Docking R, Li J, Chan S, Umlandt P, Fuller M, Jädersten M, Hellström-Lindberg E, Platzbecker U, Parker J, Karsan A. RUNX1 Loss of Function Drives Resistance to Lenalidomide in Del(5Q) Myelodysplastic Syndrome Patients. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30178-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
96
|
|
97
|
Högmander M, Paul CJ, Chan S, Hokkanen E, Eskonen V, Pahikkala T, Pihlasalo S. Luminometric Label Array for Counting and Differentiation of Bacteria. Anal Chem 2017; 89:3208-3216. [DOI: 10.1021/acs.analchem.6b05142] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Milla Högmander
- Department
of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland
| | - Catherine J. Paul
- Applied
Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-22100 Lund, Sweden
- Water
Resources Engineering, Department of Building and Environmental Engineering, Lund University, P.O. Box 118, SE-22100 Lund, Sweden
| | - Sandy Chan
- Applied
Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-22100 Lund, Sweden
- Sweden
Water Research, Ideon Science Park, Scheelevägen 15, SE-22370 Lund, Sweden
| | - Elina Hokkanen
- Department
of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland
| | - Ville Eskonen
- Laboratory
of Materials Chemistry and Chemical Analysis, Department of Chemistry, University of Turku, Vatselankatu 2, FI-20500 Turku, Finland
| | - Tapio Pahikkala
- Department
of Information Technology, University of Turku, Vesilinnantie
5, FI-20500 Turku, Finland
| | - Sari Pihlasalo
- Department
of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland
- Applied
Microbiology, Department of Chemistry, Lund University, P.O. Box 124, SE-22100 Lund, Sweden
- Laboratory
of Materials Chemistry and Chemical Analysis, Department of Chemistry, University of Turku, Vatselankatu 2, FI-20500 Turku, Finland
| |
Collapse
|
98
|
Krop I, Abramson V, Colleoni M, Holmes FA, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly CM, Uppal H, Tudor IC, Peterson A, Winer E, Yardley DA. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- I Krop
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - V Abramson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Colleoni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - FA Holmes
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Estevez
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Hart
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Awada
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - C Zamagni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - P Morris
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Schwartzberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - S Chan
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - D Wheatley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Guculp
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Biganzoli
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - J Steinberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Gianni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Trudeau
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - CM Kelly
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - H Uppal
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - IC Tudor
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Peterson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - DA Yardley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| |
Collapse
|
99
|
Dela Cruz MA, Roy P, Chowdhury S, Chan S, Roy HK. Abstract P3-07-18: Exercise and triple negative breast cancer: Unravelling the anti-neoplastic molecular factors through novel culture method. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-07-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Despite advances to ameliorate breast cancer survival, triple negative breast cancers (TNBCs) attribute to highly disproportionate mortalities due to its aggressiveness and poor therapeutic response (Bao et al., Cancer Medicine 2014). Despite the lack of target-specific drugs, chemotherapy is the mainstay treatment, warranting more efficacious measures against TNBCs. Studies have shown that physical activity intervention reduced breast cancer risk between 20-80% (Monnikohf et. al., Epidemiology 2007) as well as breast cancer related mortality by 34% (Ibrahim et al., Med Onc 2010). However, it is clear that such intervention uptake in the population may not be feasible given the longstanding public health drive to increase physical activity. Therefore it is imperative to identify the molecular factors that might be involved in cancer prevention and therapy with the long term goal of developing a supplement. Due to the recent epidemiological findings on exercise and breast cancer, we wanted to develop a system to comprehensively identify beneficial myokines using a cell culture system.
Methods
For this study we differentiated C2C12 myoblasts into myotubules. Myotubules were contracted in Krebs Ringer Buffer solution with the C-Pace EP Pacer for 8 hours. Buffer was collected and concentrated using Amicon Ultra-0.5 centrifugal filter tubes to produced an exercise/conditioned medium. To explore the effects of exercise on breast cancer cell lines MCF-7 (ER+) and MDA-MB468 (TNBC line) were treated with conditioned medium for 48 hrs. To explore the effects of exercise and chemotherapeutic efficacy MDA-MB468 cells were treated with doxorubicin, conditioned medium or both for 48 hrs. Protein was isolated and processed for immunoblot analysis. Cell cycle markers p21, pRb, cyclin D1, PCNA as well as apoptotic marker cPARP were assessed to reveal the effects treatment.
Results
Treatment of conditioned medium in MCF-7 revealed marked changes in both p21 (92% increase, p=0.05) and pRb protein expression (62% decrease, p<0.05) as well as a modest reduction in PCNA (24% decrease , p<0.02). Conditioned medium treatment in MDA-MB468 cells showed a reduction in cyclin D1 and PCNA expression (40%, p<0.01 and 30%, p<0.02) as well as an induction of cPARP expression (32%, p=0.09). Doxorubicin treatment increased p21 and cPARP protein expression (2.2-fold increase, p<0.01 and 80% increase, p<0.05 respectively). Treatment of conditioned medium and doxorubicin displayed a synergistic effect with a 3.65-fold increase in p21 (p<0.01) and 130% increase in cPARP (p=0.01).
Conclusions
We have developed a novel system that may enable, for the first time, mechanistic studies to elucidate the role of skeletal muscle/exercise in breast cancer prevention and chemotherapy. Our data indicates a secreted factor(s) from skeletal muscles that plays a role in anti-proliferative and pro-apoptotic effects, which are the hallmark of exercise's anti-neoplastic properties. Studies are ongoing to further understand, characterize and isolate this factor(s) for therapeutic purposes. Given the limited chemotherapeutic options and heterogeneity in TNBC, our exercise culture system sheds a promising light on novel drug development and chemo-sensitization.
Citation Format: Dela Cruz MA, Roy P, Chowdhury S, Chan S, Roy HK. Exercise and triple negative breast cancer: Unravelling the anti-neoplastic molecular factors through novel culture method [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-07-18.
Collapse
Affiliation(s)
| | - P Roy
- Boston University Medical Center, Boston, MA
| | - S Chowdhury
- Boston University Medical Center, Boston, MA
| | - S Chan
- Boston University Medical Center, Boston, MA
| | - HK Roy
- Boston University Medical Center, Boston, MA
| |
Collapse
|
100
|
Krop I, Cortes J, Miller K, Huizing MT, Provencher L, Gianni L, Chan S, Trudeau M, Steinberg J, Sugg J, Liosatos M, Paton VE, Peterson A, Wardley A. Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-08] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Androgen receptor (AR) expression has been observed in up to 77% of human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC).References:1 Enzalutamide (ENZA) is a potent AR inhibitor approved for patients (pts) with metastatic castration-resistant prostate cancer. In vitro, ENZA enhances antitumor activity of trastuzumab in HER2+ AR+ cell lines and inhibits proliferation in trastuzumab-resistant HER2+ cell lines.2
Methods:Pts with metastatic or locally advanced BC that was HER2+ AR+ by local or central laboratory assessment were enrolled in a single-arm, Simon 2-stage phase 2 study (NCT02091960). Key eligibility criteria included availability of a tissue sample, presence of measurable or evaluable disease per RECIST v1.1, progression on prior trastuzumab and ≥1 prior line of anti-HER2 therapy as the most recent regimen. Brain metastases and history of seizure were exclusionary. Evaluable pts were those with centrally confirmed nuclear AR expression≥10% by immunohistochemistry who received ≥1 dose of ENZA and had ≥1 postbaseline tumor assessment. Pts received ENZA 160 mg daily and trastuzumab 6 mg/kg every 21 days until disease progression. The primary objective was clinical benefit rate at 24 weeks (CBR24), defined as complete or partial response (CR or PR) or stable disease (SD) for ≥24 weeks in evaluable pts. Additional endpoints included safety and progression-free survival (PFS). CBR24 in ≥3 of 21 evaluable pts was required to continue to stage 2 and enrollment of up to 66 evaluable pts total. This design yields a 1-sided type 1 error of 5% and 90% power when the true response is 25%.
Results:Here we present results from stage 1 (data cutoff: Mar 23, 2016), with 22 evaluable pts enrolled (pts 21 and 22 enrolled simultaneously); 18 had received ≥4 prior lines of therapy. Median duration of ENZA exposure was 144 days (range, 22-495), mean number of complete trastuzumab infusions was 6.5. CBR24 was 27.3% (95% confidence interval [CI], 10.7-50.2); 2 confirmed PR and 4 SD ≥24 weeks. Median PFS was 108 days (95% CI, 56-144). All pts experienced ≥1 adverse event (AE) any grade; 5 pts experienced AEs grade ≥3. ENZA-related AEs were reported in 16 pts (72.7%), the most common (in ≥10% of pts) were fatigue (22.7%), nausea (18.2%), diarrhea (13.6%) and arthralgia (13.6%). Serious AEs were reported in 6 pts (27.3%; 2 each of infection and back pain, 1 each of abdominal pain, nausea, vomiting, pyrexia, urinary retention and pulmonary edema). Two pts discontinued due to drug-related AEs: 1 related to both drugs, 1 related to trastuzumab. One on-study death from pulmonary edema was reported, which was not considered related to either drug.
Conclusion:Stage 1 met its primary objective. No new safety signals were identified, and the safety profile in this study was similar to that in men with prostate cancer and women with other BC subtypes treated with ENZA. These results are encouraging for a heavily pretreated population with advanced HER2+ AR+ BC. Enrollment in stage 2 continues with the combination of ENZA and trastuzumab.
1. Micello D et al. Virchows Arch. 2010;457:467-476.
2. Richer J. Presented at AACR Advances in Breast Cancer, San Diego, CA, 2013.
Citation Format: Krop I, Cortes J, Miller K, Huizing MT, Provencher L, Gianni L, Chan S, Trudeau M, Steinberg J, Sugg J, Liosatos M, Paton VE, Peterson A, Wardley A. A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-08.
Collapse
Affiliation(s)
- I Krop
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Cortes
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - K Miller
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - MT Huizing
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - L Provencher
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - L Gianni
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - S Chan
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - M Trudeau
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Steinberg
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Sugg
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - M Liosatos
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - VE Paton
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - A Peterson
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - A Wardley
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| |
Collapse
|